Japan Pharmaceutical Spray Drying Market Overview, 2031

Insight Industry Ecosystem Analysis Japan’s pharmaceutical spray drying market sits at the intersection of formulation science, fine-chemical manufacturing, inhalation therapeutics, biologics and contract development rather than conventional bulk pharmaceutical production. Spray drying converts a liquid formulation into a controlled powder by atomizing feed into a heated drying chamber, with particle engineering used to control moisture, density, solubility and aerodynamic behavior. Nippon Kayaku, Astellas Pharma, Takeda Pharmaceutical, Eisai, Shionogi, Rohto Pharmaceutical, Fujifilm, Asahi Kasei and Shimadzu participate across the wider pharmaceutical, formulation-equipment or analytical ecosystem. Tokyo and Osaka remain major pharmaceutical R&D centers, while Toyama, Shizuoka, Kanagawa and Saitama provide important manufacturing and life-science clusters. Equipment and process-development supply chains also connect with Nagoya Port, Yokohama Port, Kobe Port and Osaka Port, which handle imported pharmaceutical ingredients, specialty chemicals and processing equipment. Laboratory spray dryers can cost several million yen, while GMP-capable pilot and production systems can require investments ranging from tens of millions to several hundred million yen depending on chamber size, containment and automation.

The Japanese ecosystem is particularly attractive for spray drying because pharmaceutical companies increasingly require precisely engineered formulations rather than simply conventional tablets or capsules. Spray drying can improve the dissolution of poorly water-soluble active pharmaceutical ingredients, stabilize selected biological materials, generate inhalable particles and create amorphous solid dispersions. PMDA, the Ministry of Health, Labour and Welfare (MHLW) and the National Institute of Health Sciences (NIHS) influence product development and manufacturing expectations, while contract organizations and equipment specialists provide scale-up capabilities. Fujifilm’s pharmaceutical manufacturing activities, for example, connect advanced process engineering with Japan’s broader CDMO ecosystem.

The value chain begins with API synthesis and formulation development before moving into feed preparation, atomization, drying, powder collection, milling or classification, filling and final dosage-form manufacturing. Critical process variables include inlet and outlet temperature, feed concentration, atomization pressure, airflow, residence time and solvent composition. In high-value pharmaceutical applications, even a 1–2% change in residual moisture or particle-size distribution can affect stability or downstream performance. Japanese manufacturers therefore place substantial emphasis on analytical process control, equipment reproducibility and validation.

Patent & Innovation Landscape Japan’s innovation landscape is concentrated around particle engineering, amorphous solid dispersions, inhalation powders, controlled-release formulations and continuous manufacturing. Takeda, Astellas, Eisai, Shionogi, Fujifilm and Asahi Kasei contribute to a wider pharmaceutical technology environment in which formulation performance and manufacturability are increasingly connected. Japanese patent development commonly focuses on the relationship between formulation composition and process conditions rather than the dryer alone.

One important technology area is amorphous solid dispersion. Spray drying can convert poorly soluble crystalline APIs into an amorphous matrix with polymers such as HPMC-based or PVP-based systems. The objective is to improve apparent solubility and dissolution while maintaining physical stability during storage.



A second area is inhalation particle engineering. Dry-powder inhalers generally require particles within a controlled aerodynamic range, commonly around 1–5 μm for respirable fractions. Spray drying provides control over particle morphology, density and surface properties, making it useful for pulmonary drug-delivery development.

A third innovation field is protein and peptide stabilization. Spray drying can produce dry formulations that may improve storage stability compared with aqueous formulations, although thermal and shear sensitivity require carefully optimized process conditions.

Another important area is closed-system and containment spray drying. Pharmaceutical manufacturers handling highly potent APIs require systems that minimize operator exposure and prevent cross-contamination. Japanese facilities increasingly evaluate contained charging, closed powder collection and automated cleaning.

Recent Technology Trends The first major trend is the movement toward small-particle pharmaceutical engineering. Developers are increasingly using spray drying to create powders with controlled size, porosity and surface morphology for inhalation and rapid-dissolution applications.

The second trend is continuous spray drying and continuous pharmaceutical manufacturing. Instead of producing discrete batches, integrated systems can connect formulation, drying and downstream processing with real-time monitoring. This can reduce batch variability and improve process visibility.

The third trend is closed-loop process control. Sensors monitor temperature, humidity, pressure and powder characteristics, allowing manufacturers to adjust process conditions automatically. Japanese manufacturers favor highly controlled production because pharmaceutical validation requires strong batch-to-batch reproducibility.

The fourth trend is high-containment processing. Potent oncology compounds, hormones and other high-potency APIs require contained spray-drying systems to protect workers and prevent environmental release.

The fifth trend is solvent recovery. Organic-solvent spray drying can create both safety and environmental challenges, encouraging investment in solvent condensation, recovery and explosion-protection systems.

The sixth trend is GMP-ready pilot equipment. Pharmaceutical developers increasingly require equipment that can move from laboratory formulation work to pilot production without completely changing process geometry.

The seventh trend is digital process analytical technology (PAT). Near-infrared spectroscopy, particle monitoring and automated control can reduce dependence on end-product testing by monitoring critical attributes during production.

The eighth trend is CDMO adoption. Smaller pharmaceutical companies increasingly outsource spray-drying development because specialized equipment can cost tens or hundreds of millions of yen and requires experienced formulation scientists.

Market Dynamics Market Driver Complex Drug Formulations The growing complexity of Japanese pharmaceutical formulations is increasing demand for particle-engineering technologies capable of improving solubility, stability and delivery performance. Poorly water-soluble compounds represent a substantial share of development candidates, making amorphous solid dispersion and spray-dried formulations commercially relevant. Pharmaceutical companies such as Takeda and Astellas can use spray drying to modify formulation characteristics without changing the underlying API molecule, potentially improving bioavailability and enabling differentiated dosage forms.

Market Challenge High Process Complexity Spray drying requires tight control over thermal conditions, feed properties, atomization and powder recovery. Small process changes can alter particle morphology, residual solvent, crystallinity or yield. GMP production therefore requires extensive process development, validation and cleaning procedures. A pharmaceutical spray-drying line can require investment of tens to hundreds of millions of yen, while specialized containment and solvent-recovery systems can push capital requirements considerably higher.

Market Trend Integrated Particle Engineering Japanese pharmaceutical developers are increasingly treating spray drying as part of an integrated formulation platform rather than a standalone drying operation. Formulation scientists combine spray drying with milling, particle classification, capsule filling, inhalation-device engineering and analytical testing. This integrated approach is particularly relevant for inhalation products and poorly soluble APIs where particle properties directly determine drug performance.

Regulatory Framework Pharmaceutical spray drying in Japan is governed primarily through the pharmaceutical manufacturing framework rather than a separate spray-drying regulation. MHLW and PMDA oversee drug quality, manufacturing controls, validation and product approvals, while manufacturers must demonstrate that the drying process consistently produces material meeting defined critical quality attributes.

The Pharmaceuticals and Medical Devices Act (PMD Act) establishes requirements for pharmaceutical manufacturing and quality management. Companies operating GMP facilities must maintain validated processes, documented cleaning procedures and appropriate control of raw materials and intermediates.

Japanese GMP requirements are particularly important for spray drying because powder properties can vary with feed concentration, temperature and atomization. Manufacturers must establish validated operating ranges and demonstrate that changes remain within acceptable quality limits.

Where organic solvents are used, facilities must also comply with workplace safety and environmental requirements covering solvent handling, ventilation and emissions. Pharmaceutical plants in Shizuoka, Toyama and Kanagawa therefore require specialized explosion protection and solvent-management systems for certain formulations.

PMDA inspections and manufacturing-site assessments can influence equipment qualification, process validation and documentation. Equipment suppliers must therefore provide sufficient design and performance information for pharmaceutical customers to demonstrate compliance.

For imported APIs and pharmaceutical intermediates entering through Kobe, Osaka or Yokohama, Japanese manufacturers must also maintain appropriate quality documentation and supplier qualification. International supply-chain disruptions during 2022–2024 increased attention to dual sourcing and domestic process capability.

Segment Analysis By Product Type Laboratory Spray Dryers are used during early formulation development, typically processing gram-to-kilogram quantities. Pharmaceutical companies and universities use them to evaluate solvent systems, polymers, atomization conditions and particle morphology before larger-scale production. Equipment prices can range from approximately ¥2 million to ¥15 million depending on automation, containment and analytical integration. Pilot Spray Dryers bridge laboratory development and commercial manufacturing. They can process substantially larger feed volumes and are essential for evaluating scale-dependent changes in heat and mass transfer. Pilot equipment can cost tens of millions of yen, especially when GMP-compatible construction and closed powder collection are included. Production Spray Dryers are designed for continuous or large-batch manufacturing. Capital costs can reach ¥100 million or more for sophisticated pharmaceutical systems with containment, solvent recovery, automated cleaning and advanced controls. GMP Spray Dryers are specialized systems engineered around pharmaceutical validation, cleanability and documentation requirements. Their premium reflects stainless-steel construction, surface-finish requirements, validated controls and containment.

By Application Amorphous Solid Dispersions represent one of the most important applications. Spray drying converts an API and polymer solution into a solid dispersion, potentially increasing dissolution and apparent solubility. This is especially valuable for poorly soluble compounds where conventional formulation approaches are insufficient. Inhalation Drug Delivery requires highly controlled particle size and aerodynamic behavior. Spray-dried particles are often engineered around respirable sizes of approximately 1–5 μm, although the optimal distribution depends on the formulation and inhalation device. Controlled-Release Formulations use spray drying to create particles containing polymers or functional excipients that modify drug release. The process can produce relatively uniform particles and encapsulated structures. Biologics Stabilization applies spray drying to selected proteins, peptides and biological materials. Developers must carefully manage temperature and formulation conditions to avoid degradation. Taste Masking uses spray drying to encapsulate bitter APIs or create particles with modified surface properties. This is particularly relevant for pediatric and orally disintegrating formulations. Solubility Enhancement uses spray drying to reduce crystallinity or create high-surface-area particles. The objective is to improve dissolution without changing the active molecule. Encapsulation uses polymer matrices to protect active ingredients and control their release. Pharmaceutical and nutraceutical manufacturers can use this technique for sensitive compounds.

By Formulation Small-Molecule Formulations account for the broadest application base because spray drying can address solubility and bioavailability limitations in conventional APIs. Biologic Formulations represent a technically demanding segment where protein stability is critical. Lower-temperature process development and excipient selection are therefore major considerations. Peptide Formulations can benefit from dry-state stabilization, although thermal and shear sensitivity limits the acceptable processing window. Combination Formulations incorporate multiple APIs or functional excipients into engineered particles. Spray drying can help produce consistent distribution when direct blending would create segregation problems.

By Dryer Technology Two-Fluid Nozzle Dryers use compressed gas to atomize liquid feed and are widely used for laboratory and pilot pharmaceutical development. They provide good control over droplet formation at relatively low feed rates. Pressure Nozzle Dryers use high-pressure liquid to generate fine droplets and are suitable for larger-scale continuous operation. Rotary Atomizer Dryers use centrifugal force to atomize feed. They can handle relatively high feed rates and are relevant to larger production systems. Closed-Cycle Spray Dryers recirculate drying gas and are particularly valuable when organic solvents or oxygen-sensitive formulations are involved. They can incorporate nitrogen circulation and solvent recovery.

By Drying Medium Air-Based Spray Drying is suitable for aqueous pharmaceutical formulations where oxidation and combustion risks remain manageable. It is the simplest configuration for many development applications. Nitrogen-Based Drying is used for oxygen-sensitive formulations and organic solvents. Closed nitrogen systems increase equipment complexity but improve process safety. Inert-Gas Drying is used where oxidation or solvent flammability requires an oxygen-controlled environment.

By Scale Laboratory Scale generally processes gram-to-kilogram quantities and is dominated by pharmaceutical R&D departments, universities and formulation laboratories. Pilot Scale processes larger quantities and is used for scale-up studies, process validation and clinical-development material. Commercial Scale supports routine pharmaceutical manufacturing and requires validated cleaning, process control and documentation. Large-Volume Contract Manufacturing is increasingly relevant as CDMOs provide spray-drying capacity to companies that do not want to purchase specialized equipment.

By End User Pharmaceutical Companies such as Takeda, Astellas and Eisai use spray drying for formulation development and selected commercial products. Their procurement decisions emphasize reproducibility, regulatory compliance and long-term equipment support. CDMOs are an increasingly important customer group because they can spread the capital cost of specialized dryers across multiple pharmaceutical projects. Facilities around Tokyo, Osaka and Shizuoka can serve domestic and international customers. Generic Drug Manufacturers use spray drying primarily where formulation differentiation, solubility enhancement or controlled release provides a technical advantage. Biopharmaceutical Companies require specialized systems for peptides, proteins and sensitive biological materials, creating demand for controlled-temperature and low-shear processing. Academic and Research Institutions including universities and AIST laboratories use small-scale spray dryers for formulation research, often processing grams rather than kilograms of material.

By Particle Size Below 1 μm particles serve specialized nano- and submicron formulation research but require highly controlled atomization and collection. 1–5 μm particles are particularly important for inhalation applications because aerodynamic behavior in the respiratory tract is strongly influenced by particle size and density. 5–20 μm particles are suitable for selected oral, encapsulated and controlled-release formulations. Above 20 μm particles are more relevant to conventional powder applications where rapid dissolution and aerosolization are not primary objectives.

By Region within Japan Kanto is the leading pharmaceutical R&D and corporate center, with Tokyo, Kanagawa and Saitama hosting pharmaceutical companies, research institutes and advanced manufacturing facilities. Kansai benefits from Osaka, Kyoto and Kobe’s pharmaceutical and biotechnology ecosystem. The region also has strong university and chemical-industry capabilities supporting formulation research. Chubu is important because Nagoya and Aichi combine advanced manufacturing with chemical and automotive industries, creating opportunities for process-engineering suppliers and industrial pharmaceutical production. Hokuriku has a strong pharmaceutical manufacturing tradition, particularly in Toyama, where established drug manufacturers and production facilities create demand for advanced powder-processing technologies. Kyushu is gaining importance through semiconductor and biotechnology investment, with Fukuoka and Kumamoto providing expanding technology ecosystems and logistics connections.

Strategic Market Perspective Japan’s pharmaceutical spray drying market is increasingly moving toward high-value formulation engineering rather than commodity drying capacity. The most attractive opportunities are concentrated in poorly soluble APIs, inhalation products, controlled-release formulations and specialized biologic or peptide powders where particle characteristics directly influence therapeutic performance.

The competitive advantage lies in combining spray-drying equipment, formulation expertise, analytical technology and GMP validation. Companies able to provide development-to-commercial scale-up are better positioned than equipment suppliers selling dryers alone.

The most important local friction remains scale-up reproducibility. A formulation that performs successfully in a 1–5 L laboratory chamber may not behave identically in a 50–500 kg/h commercial dryer because heat-transfer rates, residence time and droplet trajectories change. Japanese pharmaceutical companies therefore place a premium on suppliers capable of demonstrating comparable critical quality attributes across laboratory, pilot and commercial equipment.

Recent Industry Developments, 2024–2025 During 2024, Japan’s pharmaceutical manufacturing ecosystem continued prioritizing domestic production resilience and advanced formulation technologies. MHLW, PMDA and NEDO maintained programs supporting pharmaceutical manufacturing capabilities and advanced process technologies, while CDMOs and pharmaceutical manufacturers continued investing in flexible manufacturing infrastructure.

In 2025, demand increasingly shifted toward specialized particle engineering for complex molecules rather than basic drying requirements. Pharmaceutical developers in Tokyo, Osaka and Toyama showed greater interest in closed processing, solvent recovery, PAT and scalable GMP equipment. Equipment suppliers consequently faced stronger requirements for documentation, validation and digital process monitoring.

For the period through 2031, the strongest growth opportunity is expected in formulations where conventional milling or granulation cannot adequately control dissolution, particle morphology or delivery performance. In Japan, spray drying will therefore remain closely linked to the development of higher-value medicines rather than competing primarily on processing volume.

Considered in this report
Historic Year: 2020
Base Year: 2025
Estimated Year: 2026
Forecast Year: 2031

Aspects covered in this report
Japan Pharmaceutical Spray Drying Market with its value and forecast along with its segments
Various drivers and challenges
Ongoing trends and developments
Top profiled companies
Strategic recommendation

By Product Type

Laboratory Spray Dryers
Production Spray Dryers
GMP Spray Dryers

By Application

Amorphous Solid Dispersions
Inhalation Drug Delivery
Spray-dried particles
Controlled-Release Formulations
Biologics Stabilization

By Formulation

Small-Molecule Formulations
Biologic Formulations
Lower-temperature process development and excipient selection
Combination Formulations

By Dryer Technology

Two-Fluid Nozzle Dryers
Pressure Nozzle Dryers
Rotary Atomizer Dryers
Closed-Cycle Spray Dryers recirculate drying gas and

By Drying Medium

Air-Based Spray Drying
Nitrogen-Based Drying
Inert-Gas Drying

By Scale

Pilot Scale processes larger quantities and
Commercial Scale
Large-Volume Contract Manufacturing

By End User

CDMOs
Facilities around Tokyo, Osaka and Shizuoka

By Particle Size

Below 1 μm particles
1–5 μm particles
5–20 μm particles
Above 20 μm particles

By Region within Japan

Kanto
Chubu
Hokuriku
Kyushu